Spyre Therapeutics (SYRE) shares soared 29% after the company said Monday its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its key targets in a phase 2 trial.

Over 4.10 million shares traded intraday, versus a daily average of roughly 747,000.

ImageneBio (IMA) reported Monday that its private placement with certain institutional investors is expected to result in gross proceeds of about $30 million to the company.

Shares jumped 22%, with intraday trading volume catapulting to more than 17.5 million from a daily average of about 38,000.

Price: 65.06, Change: +13.77, Percent Change: +26.85